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Abstract
Background: High-throughput technologies like functional screens and gene expression analysis
produce extended lists of candidate genes. Gene-Set Enrichment Analysis is a commonly used and
well established technique to test for the statistically significant over-representation of particular
pathways. A shortcoming of this method is however, that most genes that are investigated in the
experiments have very sparse functional or pathway annotation and therefore cannot be the target
of such an analysis. The approach presented here aims to assign lists of genes with limited
annotation to previously described functional gene collections or pathways. This works by
comparing InterPro domain signatures of the candidate gene lists with domain signatures of gene
sets derived from known classifications, e.g. KEGG pathways.
Results: In order to validate our approach, we designed a simulation study. Based on all pathways
available in the KEGG database, we create test gene lists by randomly selecting pathway genes,
removing these genes from the known pathways and adding variable amounts of noise in the form
of genes not annotated to the pathway. We show that we can recover pathway memberships based
on the simulated gene lists with high accuracy. We further demonstrate the applicability of our
approach on a biological example.
Conclusion: Results based on simulation and data analysis show that domain based pathway
enrichment analysis is a very sensitive method to test for enrichment of pathways in sparsely
annotated lists of genes. An R based software package domainsignatures, to routinely perform this
analysis on the results of high-throughput screening, is available via Bioconductor.
Background
Many high-throughput techniques such as DNA microar-
ray analysis, siRNA screens or proteomic approaches
result in extensive data. After careful statistical analysis the
result of such an experiment is typically a list of candidate
genes, relevant for certain biological processes, or an
ordered gene list, sorted according to the significance in
one or more biological processes [1]. The data analysis
and interpretation of such lists provides a major bottle-
neck and a task for bioinformatics and systems biology.
Many approaches have been published that assess the sig-
nificant over-representation of biological functions or
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pathways as annotated in GO or pathway databases
through gene set enrichment analysis [2-8].
However, for many of the screened genes there is hardly
any functional annotation available. For example, the
number of human genes annotated in the KEGG database
[9] is only about 4,000. This contrasts the estimated
number of putative protein coding genes which exceeds
23,000 (counted as the number of Entrez gene ids in the
IPI-human database) [10,11]. Many approaches rely on
automatically inferred functional annotations [12]. Such
annotations can be assigned, for example, based on the
protein sequences and predicted domains, as well as on
protein interactions or co-expression. Structured vocabu-
laries such as the Gene Ontologies (GO) comprise many
such kinds of annotation [1].
Especially interesting and accessible is the functional
annotation that is based on predicted protein domains, as
there are already highly reliable prediction methods and
databases available. Of the 23,000 genes in the IPI-human
database, approximately 19,000 have at least one Inter-
Pro-domain assigned, of the 4,000 genes in the human-
KEGG pathways, nearly all have at least one InterPro-
domain. Together, these comprise approximately 3,000
distinct InterPro-domains [13]. Protein domains very
often directly correspond to some of the core biological
functions, such as e.g. DNA binding, kinase or phosphor-
ylation activity, or otherwise to cellular localization.
Therefore, predicted protein domains are often utilized to
predict these annotations, for instance in the GO data-
base. To our knowledge, however, protein-domain signa-
tures have thus far not been used as a classifier to predict
assignment of genes to pathways, which constitute the
biological processes in a cell. Here we want to critically
assess the utility of domain information to predict path-
way membership and provide a tool to utilize this infor-
mation. As we deem it unlikely to reliably predict pathway
memberships for individual genes, our main aim is to find
relevant pathways significantly enriched in lists of genes,
in particular lists from high-throughput experiments.
Pathways consist of a series of chemical reactions occur-
ring within a cell. Of special importance for the function-
ing of biological systems are the signalling pathways, in
which signals or cellular stimuli are transmitted mainly
through protein interaction and phosphorylation events,
often leading to altered gene expression within a cell.
Known signalling pathways are collected within different
pathway databases [14]. Pathways thus represent func-
tional units for collecting genes or proteins. Crucial to
gain hints of the function of genes is the mapping of these
to one or more known pathways.
In many high-throughput experiments, we are facing the
problem that we want to test for enrichment of pathways
in gene lists, but the genes are often not annotated to
pathways at all, or may even lack any form of functional
annotation. We tried to answer this problem with the fol-
lowing idea: It should be possible to map a high fraction
of the human genes to pathways via their protein
domains. Hypothesis: Protein domains can be treated as
functional elements of the proteins, the set of interpro-
domains of the proteins of one pathway could serve as its
functional fingerprint. In order to test the validity of this
idea, we designed a simulation study based on the KEGG
database and the protein domain assignment in the IPI
database. Virtually removing genes from the KEGG path-
ways, we demonstrate that we can place these genes back
into the respective pathway with high accuracy. We have
further applied the method to a biological dataset from a
high-throughput siRNA screen and demonstrate, that we
are able to get biologicaly meaningful results.
Results and Discussion
We have developed a novel approach in order to test for
the enrichment of pathways in arbitrary lists of genes. This
approach is based on comparing the protein domain
composition of the gene list of interest with the domain
signature of the set of genes in each particular pathway. A
more detailed description of this approach and a discus-
sion of different measures of similarity, that can be uti-
lized for this analysis, can be found in section Similarity
Measure. We have tested the validity of this approach in a
simulation study based on splitting the gene lists of
known pathways from the KEGG database. We demon-
state that the method works well for most known path-
ways even in the cases of noisy gene lists and pathway
mixtures, at least for gene lists that contain 5 or more
pathway genes. We suggest an approach to assess the sig-
nificance of the resulting scores based on a resampling
method in section Assessment of significance and test sensi-
tivity and specificity in the assignment of pathway mix-
tures in section Simulation of pathway mixtures. Finally, we
demonstrate the utility of our approach on a real biologi-
cal dataset and discuss its interpretation. The method and
simulation strategy is illustrated in Figure 1.
Similarity Measure
There are different approaches to derive measures of sim-
ilarity between the domain signatures of two distinct sets
of genes. In the simplest case this is a binary distance
based on the existence of a domain in a set of genes. We
can create a binary vector reporting for each possible
domain, whether it is part of any gene in the set or not and
compute, for example, the Hamming distance between
two vectors. However, this does not take into account the
multiple appearances of domains in several genes of the
set. In contrast, vectors of integer values reporting the
number of appearance of all domains in the sets can be
compared using simple Euclidean distance. During theBMC Bioinformatics 2008, 9:3 http://www.biomedcentral.com/1471-2105/9/3
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development of the simulation strategy, we tested several
different similarity measures, and showed that they led to
comparable results. Here, we focus on a similarity meas-
ure that is more robust to deviations in the sizes of the
sets, which is based on the chi-square statistic. For the two
sets we count:
1. the number of intersecting domains for both sets,
2. the number of domains that are unique to set 1,
3. the number of domains that are unique to set 2,
4. the number of domains not part of any of the two sets.
By means of a binomial test, we compute on this contin-
gency table the probability of over-representation of
domains of set 1 in set 2 given all available domains. The
negative log-transform of this probability can now be
used as a measure for signature similarity. Note that
higher values indicate a higher similarity between the two
sets.
Simulation Strategy
In order to assess whether InterPro domains can be used
as a tool for functional classification we conducted a sim-
ulation experiment. We chose the pathways represented
in the KEGG database as test environment, since this data-
base is readily available. In principle, however, the
method should be applicable to any kind of functional
classification. Assuming, that the domain structure of
either a single protein or, more likely, of a group of pro-
teins with related function should be sufficient for func-
tional classification (i.e. to assign a pathway
membership), we sampled different numbers of genes
that are known to be part of a given KEGG pathway. These
genes were then removed from the pathway to construct
somewhat smaller virtual pathways, which were used in
the further test. In a subsequent step, we tried to recover
the pathway membership of the collections of removed
genes, based on the computed similarity of their domain
signature to the domain signature derived from all
remaining proteins of the respective pathway. To assess
the significance of this score, the similarity measure of the
sampled genes was compared to that of a control subset
consisting of randomly chosen genes not specifically
annotated to the respective pathway. We expect the latter
to be less similar to the pathway signature.
Simulating a single pathway
In an initial approach we chose a single non-metabolic
pathway (hsa04650, natural killer cell mediated cytotox-
icity) that comprises a high number of 126 annotated
genes. For this pathway, we randomly sampled increasing
Simulation work flow Figure 1
Simulation work flow. For the simulation study we sampled increasing numbers of genes from a given pathway and the same 
number of random genes. Genes that were present in both the pathway and the gene lists were removed from the pathway 
definition. Interpro domain signatures were constructed for both gene lists and for the pathway and measures of significance 
between gene lists and pathway were computed. This procedure was repeated 1,000 times and the resulting similarty meas-
ures were recorded.
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numbers of member genes and computed the similarity
measure to the remaining pathway genes. In parallel, the
same increasing numbers of random genes that have not
been specifically annotated to hsa04650 were sampled
and the similarity was computed. For each number of
genes, we repeated this procedure 1,000 times. In order to
avoid over-fitting, the sampled pathway genes were
removed from the data set used to train the classifier,
hence they did not contribute to the global pathway sig-
nature they were compared against. The plot in Figure 2a
shows the comparison of the computed similarities.
While the domain signature of the random genes is not
very similar to the pathway signature and stays more or
less constant over different numbers of genes, we see a
steady increase in similarity for increasing numbers of
sampled pathway genes. Based on the signature of only
two pathway genes we can already distinguish between
the random sample and the pathway genes. The sampling
variance indicated by the error bars is extremely low.
Simulating all 181 pathways
In a second step, we performed a similar simulation for all
181 KEGG pathways, this time sampling sets containing
from one up to ten pathway genes, each 1,000 times. To
assess how well the pathway gene similarity and the ran-
dom sample similarity separate, we computed ROC curves
for each pathway and each sample number and, subse-
quently, the area under the curve (AUC) as a measure of
separation. ROC curves are plots of the true positive rate
against the false positive rate at different cutoff levels of a
binary classifier. Thus, an AUC of 1 represents an ideal
classification while an AUC of 0.5 is what can be achieved
by random guessing. In the box plots in Figure 2b we plot
the distribution of AUC values for all 181 pathways for
the different numbers of sampled genes. For most of the
pathways we achieve almost complete separation with
only a small number of sampled genes. Already for two
sampled genes, the bulk of the data lies above 0.9 indicat-
ing low misclassification rates. Sampling of five genes is
sufficient to achieve complete separation for the majority
of the 181 pathways. Still, some of the pathways can not
be classified at all, or only very poorly. Detailed analysis
of these pathways revealed that they often comprise only
small numbers of proteins or that they belong to the class
of metabolic pathways. In both cases, this result can be
expectet: For small pathways we run into problems during
the sampling process, because due to the removal of genes
from the training set, we end up with sparse domain sig-
natures based on a very small number of genes. Moreover,
we do not expect a good performance of our method for
many of the metabolic pathways since they are based on a
functional classification that may only be weakly reflected
in the composition of protein domains. Most of these
domains are extremely unspecific, leading to a poor spe-
cificity of the overall domain signature. A detailed list of
the performance of all 181 pathways can be found as
Additional file 2.
Pathway classification Figure 2
Pathway classification. Simulated classification of KEGG pathways based on a binomial similarity measure. a) Single pathway 
(hsa04650, natural killer cell mediated cytotoxicity). The red curve shows the similarity to the pathway for increasing numbers 
of sampled pathway genes. The blue curve shows the similarity to the pathway for increasing numbers of random genes. Each 
point comprises an average from 1000 independent samples and the sampling variance indicated by the error bars is negligible. 
b) Results for all 181 KEGG pathways. The boxplots show AUC values indicating the amount of separation between 1,000 ran-
dom sampled gene lists and lists containing pathway genes for all pathways, again sampling increasing numbers of genes.
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Simulating noisy data
In the previous sections, we based our simulations on
ideal data, i.e. the gene list consisted purely of genes from
a certain pathway. In a real application we will rather have
to deal with gene lists that also contain 'noise genes' that
do not belong to the respective pathway, or with a mixture
of genes from several different pathways. In order to
reflect this noise contribution, we extended our simula-
tion strategy. Along with the pathway genes, we sampled
a fixed number of 50 random genes, that are not anno-
tated to the pathway of interest. Again, we computed sim-
ilarity measures for theses sets and for random control sets
and plotted the results (Figure 3). For the single pathway
hsa04650 we can again clearly differentiate between the
random gene sets and the gene set containing pathway
genes. Absolute values of the similarity measures are
lower compared to the 'clean' data set reflecting the noise
contribution. The sample variance is again negligible.
Upon application to all pathways the random gene sets
can again be clearly separated from pathway gene sets
based on only a small number of genes. For five genes in
a list containing 50 noise genes we can almost perfectly
separate the majority of all pathways.
Assessment of significance
In order to apply our method to real biological data, one
has to derive a measure of significance indicating that the
similarity of the gene list to a given pathway is not merely
by chance. Since we do not have a clear concept of proba-
bility distributions or statistical models of the highly com-
plex pathway data, we applied a non-parametric sampling
method to derive p-values for statistical significance. To
this end, we sample for each pathway 10,000 random
gene lists of the same size as the gene list analysed and
compute their similarities to the pathway domain signa-
ture. The p-value is defined as the fraction of data points
in this empirical distribution larger than the similarity
measurement of the original gene list.
Simulation of pathway mixtures
Further, we studied in how far this approach is applicable
for gene lists that contain genes from more then one path-
way in addition to noise genes. We performed a simula-
tion study and estimated the expected sensitivity versus
specificity tradeoff of our method, meaning how many of
these pathways we can recover and how many are lost. To
this end we simulated putative gene lists, each containing
5 genes from either 3, 5 and 10 different randomly
selected pathways, and added further 50 noise genes – so
the total sizes of the simulated gene lists were 65, 75 and
100 genes, respectively. This procedure was repeated 100
times. Pathways were considered over-represented when
the resulting p-values from our method were below 0.01.
Subsequently, we computed sensitivity and specificity
percentages from the total number of false positive and
false negative pathway assignments (Figure 4). The 20
pathways showing domain signatures of very low predic-
tive power (i.e. very small pathways with AUC < 0.7) as
identified in the previous simulation were not regarded
here. Based on these findings, our method is able to
recover pathways with high accuracy both in terms of sen-
sitivity and specificity of more than 90%. The slightly
lower specificity values may be explained by the partially
hierarchical structure of KEGG, with some of the path-
ways being part of other, more extended pathways (see
Pathway classification with noisy data Figure 3
Pathway classification with noisy data. Simulated classification of KEGG pathways after addition of noise in the form of 
random genes that are not assigned to the respective pathways. The number of noise genes was fixed to 50. The similiarity 
measures and graphs are produced similar as for Figure 2. a) single pathway b) all 181 KEGG pathways.
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Additional file 2 for estimates of similarities between indi-
vidual KEGG pathways)
Application to screening data
In order to demonstrate the applicability of our approach,
we tested the method on a data set generated in the
department in a genome wide high-throughput screen
aiming to identify modulators of cell adhesion. This
screen resulted in a list of approximately 1,000 candidate
proteins. Application of our method revealed a significant
similarity to the domain signature of the KEGG pathway
hsa00531 for glycosaminoglycan degradation. Gly-
cosaminoglycans (GAG) are linear polysaccharides built
from disaccharidic units and they are covalently attached
to core proteins, forming proteoglycans (PG) [15]. They
provide mechanical links between the extracellular matrix
and the cell surface, which influence signal transduction
pathways and the cytoskeleton [16,17]. Proteins involved
in glycosaminoglycan degradation are essential compo-
nents in the regulation of GAG and PG functions. Down-
regulation of genes involved in glycosaminoglycan degra-
dation induces loss of cell adherence, and tumor stroma
contains proteoglycans and glycosaminoglycans often in
higher proportion than normal tissue [18]. As the biolog-
ical role of the KEGG pathway hsa00531 fits to the pheno-
type which we screened with the assay for cell
detachment, we conclude that our method is suitable for
application to high-throughput data, revealing relevant
proteins for potentially any cellular process. Furthermore,
we could not detect a significant over-representation of
hsa00531 in a classical hypergeometric test based on
available KEGG annotations, indicating that our method
adds additional information to gene lists compared to
well established techniques.
Conclusion
We have established a technique to use predicted protein
domains in order to test for enrichment of pathways
based on the domain signatures of the gene lists of inter-
est. In a simulation study we show that our method can
reliably predict the pathway membership of genes that
were previously removed from a database of known path-
ways. To our knowledge, this approach is unique to assign
pathway membership based on sequence information.
This is important for prediction of biological functions
and the basis for systems biological approaches. We dem-
onstrate the applicability of our method in the functional
analysis of high-throughput siRNA screening data and
identify the enrichment of a biologically significant path-
way in a poorly annotated gene list. This strategy will
improve the field of gene set enrichment analysis and help
to point out the biologically meaningful aspect of gene
sets. The method is available as open source software in
the Bioconductor package domainsignatures [19].
Methods
Databases
Gene to pathway mapping was done using information
obtained as tab-delimited text files from the KEGG FTP-
site [20], files hsa_pathway.list and hsa_ncbi-geneid.list.
The files used in this analysis were downloaded in
November 2006 and contain references to 181 pathways
including 4,085 genes. The mapping of proteins to Inter-
Pro-domains was based on the information stored in the
IPI database. The database files were downloaded from
the IPI web site [21] in November 2006. This version of
the IPI database contains 23,423 human genes (coding for
at least one protein) and information for 3,968 genes
which are also listed in the KEGG database. The Entrez
GeneID [22] was used as the universal identifier. On aver-
age, each pathway contains 46,6 genes and 68.1 unique
domains. On average each protein in the KEGG database
has 3.5 unique domains. Each domain on average appears
in 3.95 different pathways. Domains appear on average in
6.7% of all genes in a pathway and there are only very few
domains that appear in the majority of genes of a path-
way. Some further statistics on the distribution of
domains in pathways and proteins are available in Addi-
tional file 2.
All databases were stored and queried via a local MS SQL
server database.
Implementation
All computations were done using the statistical program-
ming language R in combination with Bioconductor
tools. We provide a software package domainsignatures
containing the means and source code to compute path-
way enrichment in gene lists based on domain signatures
(Additional file 1). The package uses the latest KEGG ver-
Sensitivity and specificity Figure 4
Sensitivity and specificity. Expected sensitivity (left) and 
specificity (right) of our method estimated through simula-
tion of 100 sampled gene lists containing genes of varying 
numbers of KEGG pathways. 5 genes were sampled from 
each of 3, 5 or 10 different pathways, respectively, plus addi-
tional 50 random noise genes were added each time. The 
sensitivity and specificity was above 90% in all cases, the sam-
pling variance indicated by the error bars is negligible.
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sion based on the Bioconductor KEGG package and the
domain annotation based on the BiomaRt package [23]
and the annotation in the Ensembl [24] database.
Detachment Assay
We used a biological dataset generated in the department
as an example to test the utility of our method on the out-
come of high-throuput experiments. The data is based on
an RNAi screening experiment utilizing a cell detachment
assay. This assay measured the number of floating cells
and thus the loss of adherence after gene knock down in
HEK293 cells transfected with siRNA pools. The siRNAs
are available from Dharmacon (Lafayette). Transfections
were performed using Lipofectamine (Invitrogen), and
after 72 hours the culture medium was centrifuged to col-
lect non-adherent cells. The cells were then fixed and
counted by flow cytometry.
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